PD-ECDF-targeted tumor imaging: Development of production system for I-123 labeled compound

• Project/Area Number: 26461782
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Hokkaido University
• Principal Investigator: Nishijima Ken-ichi 北海道大学, 大学病院, 薬剤師 (60364254)
• Co-Investigator(Kenkyū-buntansha): 大倉 一枝 北海道医療大学, 薬学部, 教授 (60094827)
• Co-Investigator(Renkei-kenkyūsha): KUGE YUJI 北海道大学, アイソトープ総合センター, 教授 (70321958) ; ZHAO SONGJI 福島県立医科大学, 福島国際医療科学センター, 教授 (80374239)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 放射性薬剤 / 癌 / チミジンホスホリラーゼ / 放射性診断薬剤 / 血管新生 / 自動合成

Outline of Final Research Achievements

The angiogenic factor PD-ECGF/ Thymidine phosphorylase (TP) is expressed at a high level in various solid tumors as compared with the normal tissue. In this study, we aimed to construct an automated manufacturing system for I-123 labeled IIMU that we have developed imaging targeting for PD-ECGF. During this research period, the solution composition of radioactive iodine as a raw material was changed. Therefore, we had to optimize the synthetic condition of I-123 labeled IIMU again. The results of study, it was possible to give I-123 labeled IIMU with the same radiochemical yield as conventional methods. The results of this research gave important knowledge for the automated manufacturing system of the I-123 labeled IIMU.

Research Products

• [Journal Article] The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine. (2016)
  • Author(s): Kobashi N, Matsumoto H, Zhao S, Meike S, Okumura Y, Abe T, Akizawa H, Ohkura K, Nishijima K, Tamaki N, Kuge Y.
  • Journal Title: Journal of Nuclear Medicine Volume: 8 Issue: 8 Pages: 1276-1281
  • DOI: 10.2967/jnumed.115.165811
  • Peer Reviewed / Open Access
• [Journal Article] イメージングによる“がん”の治療効果予測 ―新規核医学診断薬（［123I］IIMU）の臨床研究への歩み― (2015)
  • Author(s): 久下 裕司，西嶋 剣一，大倉 一枝，志賀 哲，玉木 長良
  • Journal Title: Isotope News Volume: 1 Pages: 16-20
  • Open Access
• [Presentation] Preclinical evaluation of thymidine phosphorylase imaging probe, [123I]IIMU, A road to First-in-human clinical study (2015)
  • Author(s): Nishijima K, Zhao S, Matsumoto H, Akizawa H, Ohkura K, Shiga T, Hirata K, Watanabe S, Okamoto S, Tamaki N, Kuge Y
  • Organizer: Ninth Japan-China Joint Seminar on Radiopharmaceutical Chemistry
  • Place of Presentation: 放射線医学総合研究所（千葉県・稲毛市）
  • Year and Date: 2015-11-08
  • Int'l Joint Research
• [Remarks] チミジンホスホリラーゼを標的とした新規イメージング剤の開発
  • URL: http://www.hokudai.ac.jp/radiois/kenkyusitu.html